Make a list of the biotech and pharmaceutical companies developing marijuana-based, or cannabis, treatments, and GW Pharmaceuticals PLC (GWPH) is most certainly going to occupy the top spot. The U.K.-based biopharmaceutical company, founded in 1998, is involved in the development of medications using its exclusive cannabinoid product platform. The company is currently assessing the potential of cannabinoids for treating a number of central nervous system disorders—multiple sclerosis and epilepsy for instance—cancer, type 2 diabetes and neurodegenerative diseases. Here are the marijuana-based treatments that GW Pharma is currently working on.
Sativex, GW Pharma’s first and its only commercially available cannabis-based medication, is an oromucosal spray—or mouth spray—currently indicated as a treatment for symptom improvement of moderate to severe spasticity due to multiple sclerosis in adult patients who haven’t responded sufficiently to other anti-spasticity treatments. The medication was derived from the cannabis plant and its active cannabinoids include tetrahydrocannabinol (THC) and cannabidiol